SEC Tracker
Get the app

Acadia Pharmaceuticals ACAD

M Daly James (Director) plans to sell 30,000 ACAD shares, about $670,983

Form
144
Filed
Importance
Routine
  1. Approximate sale date: Nov 10, 2025
  2. Broker: Morgan Stanley Smith Barney LLC Executive Financial Services
  3. Shares acquired by: Restricted Stock

All of M Daly James's insider filings, holdings and planned sales

Form 4s that likely executed this notice (SEC Tracker's match by person, company, dates and shares):

  • Sold 30,000 shares at $22.37 on Nov 10, 2025 · Form 4

Written from the Form 144 on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Acadia Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Twist Bioscience TWST public float $2.3B, Mar 31, 2025, over 18 months old
  2. Xenon Pharmaceuticals XENE public float $2.4B, Jun 30, 2025
  3. Summit Therapeutics SMMT public float $2.5B, Jun 30, 2025
  4. Cytokinetics CYTK public float $2.5B, Jun 30, 2025
  5. TG Therapeutics TGTX public float $2.5B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.